Flucytosine
Ancobon, Flucytosine (flucytosine) is a small molecule pharmaceutical. Flucytosine was first approved as Ancobon on 1982-01-01. It is used to treat aids-related opportunistic infections, aspergillosis, candidiasis, chromoblastomycosis, and cryptococcal meningitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ancobon (generic drugs available since 2011-06-28)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Flucytosine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ANCOBON | Bausch Health Companies | N-017001 RX | 1982-01-01 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ancobon | New Drug Application | 2022-02-02 |
| flucytosine | ANDA | 2024-01-30 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AE: Other antifungals for topical use in atc
— D01AE21: Flucytosine
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AX: Other antimycotics for systemic use in atc
— J02AX01: Flucytosine
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cryptococcal meningitis | D016919 | EFO_0007228 | B45.1 | 1 | 4 | 3 | 1 | 9 | 17 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 8 | 4 | 2 | — | — | 10 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | 1 | — | 6 | 9 |
| Astrocytoma | D001254 | EFO_0000271 | — | 6 | 2 | 2 | — | — | 8 |
| Oligodendroglioma | D009837 | EFO_0000631 | — | 5 | 1 | 1 | — | — | 6 |
| Hiv | D006678 | — | O98.7 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 4 | 2 | — | — | — | 4 |
| Gliosarcoma | D018316 | — | — | 3 | 1 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 3 | 2 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 3 | 2 | — | — | — | 3 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 1 | 1 | — | — | — | 1 |
| Digestive system neoplasms | D004067 | — | — | 1 | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | — | — | — | — | 3 |
| Glioma | D005910 | EFO_0000520 | — | 2 | — | — | — | — | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | 2 | — | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | 2 | — | — | — | — | 2 |
| Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Food-drug interactions | D018565 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Flucytosine |
| INN | flucytosine |
| Description | Flucytosine is an organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections. It has a role as a prodrug. It is an organofluorine compound, a pyrimidone, an aminopyrimidine, a nucleoside analogue and a pyrimidine antifungal drug. It is functionally related to a cytosine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(=O)[nH]cc1F |
Identifiers
| PDB | — |
| CAS-ID | 2022-85-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1463 |
| ChEBI ID | 5100 |
| PubChem CID | 3366 |
| DrugBank | DB01099 |
| UNII ID | D83282DT06 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,744 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ancobon, Flucytosine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
506 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use